NCT06482788View on ClinicalTrials.gov

Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2027

Conditions
Esophagogastric Junction Adenocarcinoma
Interventions
DRUG

Adebrelimab (anti-PD-L1) + XELOX

"Adebrelimab: 1200mg, i.v., each infusion lasts 30-60 minutes and is administered on the first day of each cycle (3 weeks).~Capecitabine: 1000mg/m2 , bid, orally, from day 1 to day 14 of each cycle (3 weeks).~Oxaliplatin: 130mg/m2, i.v., each infusion is administered on the first day of each cycle (3 weeks)."

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER